Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
Coya Therapeutics (NASDAQ: COYA) reported Q3 2024 financial results and corporate updates. Key highlights include positive results from a low-dose IL-2 study in Alzheimer's Disease, patent filings for COYA 301 with GLP-1 receptor agonists, and leadership changes with Arun Swaminathan becoming CEO. The company's cash position was $31.1 million as of September 30, 2024. Q3 net loss increased to $4.0 million from $3.4 million year-over-year. R&D expenses rose to $2.2 million from $1.6 million, while G&A expenses increased slightly to $2.2 million from $2.0 million.
Coya Therapeutics (NASDAQ: COYA) ha riportato i risultati finanziari e aggiornamenti aziendali del terzo trimestre del 2024. I punti salienti includono risultati positivi da uno studio a basso dosaggio di IL-2 nella malattia di Alzheimer, domande di brevetto per COYA 301 con agonisti del recettore GLP-1 e cambiamenti nella leadership con Arun Swaminathan che diventa CEO. La posizione di cassa dell'azienda era di 31,1 milioni di dollari al 30 settembre 2024. La perdita netta del terzo trimestre è aumentata a 4,0 milioni di dollari rispetto ai 3,4 milioni dell'anno precedente. Le spese per R&S sono aumentate a 2,2 milioni di dollari rispetto a 1,6 milioni, mentre le spese generali e amministrative sono leggermente aumentate a 2,2 milioni di dollari rispetto a 2,0 milioni.
Coya Therapeutics (NASDAQ: COYA) reportó los resultados financieros del tercer trimestre de 2024 y actualizaciones corporativas. Los aspectos más destacados incluyen resultados positivos de un estudio de IL-2 a baja dosis en la enfermedad de Alzheimer, solicitudes de patente para COYA 301 con agonistas del receptor GLP-1 y cambios en la dirección con Arun Swaminathan convirtiéndose en CEO. La posición de efectivo de la compañía era de 31,1 millones de dólares al 30 de septiembre de 2024. La pérdida neta del tercer trimestre aumentó a 4,0 millones de dólares desde 3,4 millones en comparación con el año anterior. Los gastos de I+D aumentaron a 2,2 millones de dólares desde 1,6 millones, mientras que los gastos generales y administrativos aumentaron ligeramente a 2,2 millones de dólares desde 2,0 millones.
Coya Therapeutics (NASDAQ: COYA)는 2024년 3분기 재무 결과 및 회사 업데이트를 보고했습니다. 주요 내용은 알츠하이머병에 대한 저용량 IL-2 연구의 긍정적인 결과, GLP-1 수용체 작용제를 포함한 COYA 301의 특허 출원, 그리고 Arun Swaminathan이 CEO로 취임하는 리더십 변화입니다. 회사의 현금 보유고는 2024년 9월 30일 기준으로 3,110만 달러였습니다. 3분기 순손실은 지난해 3.4백만 달러에서 4.0백만 달러로 증가했습니다. 연구개발(R&D) 비용은 160만 달러에서 220만 달러로 증가했으며, 일반관리(G&A) 비용은 200만 달러에서 220만 달러로 약간 증가했습니다.
Coya Therapeutics (NASDAQ: COYA) a annoncé les résultats financiers et les mises à jour corporatives du troisième trimestre 2024. Les points clés incluent des résultats positifs d'une étude à faible dose d'IL-2 dans la maladie d'Alzheimer, des dépôts de brevets pour COYA 301 avec des agonistes du récepteur GLP-1 et des changements de direction avec Arun Swaminathan devenant PDG. La position de trésorerie de l'entreprise était de 31,1 millions de dollars au 30 septembre 2024. La perte nette du troisième trimestre a augmenté à 4,0 millions de dollars contre 3,4 millions d'une année sur l'autre. Les dépenses de R&D ont augmenté à 2,2 millions de dollars contre 1,6 millions, tandis que les dépenses générales et administratives ont légèrement augmenté à 2,2 millions de dollars contre 2,0 millions.
Coya Therapeutics (NASDAQ: COYA) berichtete über die finanziellen Ergebnisse und Unternehmensupdates für das 3. Quartal 2024. Zu den wichtigsten Punkten gehören positive Ergebnisse einer Low-Dose-IL-2-Studie zur Alzheimer-Krankheit, Patentanmeldungen für COYA 301 mit GLP-1-Rezeptoragonisten und Veränderungen in der Führungsebene, wobei Arun Swaminathan CEO wird. Die Liquiditätsposition des Unternehmens betrug am 30. September 2024 31,1 Millionen Dollar. Der Nettoverlust im 3. Quartal stieg von 3,4 Millionen auf 4,0 Millionen Dollar im Vergleich zum Vorjahr. Die F&E-Ausgaben stiegen von 1,6 Millionen auf 2,2 Millionen Dollar, während die allgemeinen Verwaltungskosten geringfügig von 2,0 Millionen auf 2,2 Millionen Dollar stiegen.
- Cash position of $31.1 million as of September 30, 2024, with $39.8 million by October 31
- Positive results from Alzheimer's Disease clinical trial
- Potential milestone payments of $8.4 million from Dr. Reddy's Laboratories upon IND acceptance
- Multiple clinical trial catalysts expected throughout 2025
- Net loss increased to $4.0 million from $3.4 million year-over-year
- R&D expenses increased by 37.5% to $2.2 million
- G&A expenses rose by 10% to $2.2 million
Insights
The Q3 update reveals significant progress in Coya's neurodegenerative disease pipeline. The positive Phase 2 data for low-dose IL-2 in Alzheimer's disease at CTAD24 strengthens the scientific rationale for COYA 302, their combination therapy. The company's dual-mechanism approach combining Treg enhancement with inflammatory cell inhibition shows promise for complex neurological conditions.
Key developments include FDA alignment on COYA-302's ALS trial requirements and potential
However, the
The financial position shows both strengths and concerns. While the
Multiple potential catalysts in 2025 could drive value, particularly the
Recent Corporate Highlights
-
Announced positive results from an investigator initiated double-blind study of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer’s Disease (AD) at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in
Madrid - Filed patents for COYA 301 in combination with Glucagon-Like Peptide-1 (GLP-1) receptor agonists
- Promoted Arun Swaminathan, Ph.D. to Chief Executive Officer, effective November 1, 2024, while Howard Berman has transitioned from CEO to Executive Chairman
- Announced anti-inflammatory effects of COYA 302 in the brain from a preclinical inflammatory mouse model of Parkinson’s disease (PD)
- Aligned with FDA on the non-clinical data needed to support the planned randomized, double-blind, placebo-controlled, Phase 2b trial of COYA-302 in patients with Amyotrophic Lateral Sclerosis (ALS).
- A Phase 1 investigator-initiated trial (IIT) combining LD IL-2 + CTLA4-Ig began in patients with Frontotemporal Dementia (FTD)
Upcoming Expected Catalysts for 2025
- Q1 2025: Additional clinical data to be released in the Phase 2 LD IL-2 investigator-initiated trial (IIT) study in patients with AD. Publication and release of additional and comprehensive blood immune panels and inflammatory cerebrospinal fluid (CSF) biomarkers comparing LD IL-2 arms to placebo arm
- Q1/Q2 2025: COYA 301/GLP-1 combination data submission for publication and additional intellectual property filings
- Q2 2025: Submission of additional data to support the start of the COYA-302 Phase 2 trial in patients with ALS
-
Upon IND acceptance and first patient dosing of COYA-302 in ALS, eligible to receive milestone payments of
from strategic partner, Dr. Reddy’s Laboratories (DRL)$8.4 million - Q2 2025: ALS Biomarker data. Publication of longitudinal data on Neurofilament Light Chain (NfL) and oxidative stress markers in patients with ALS
- 2H 2025: Top-line clinical data release for an investigator-initiated trial combining LD IL-2 + CTLA4-Ig in patients with FTD
-
2H 2025: Filing of IND for the COYA-302 Phase 2 trial in patients with FTD*
(*Clinical trial initiated upon FDA IND approval)
“We are pleased with the constructive discussion we have had with the FDA,” said Coya CMO, Dr. Fred Grossman. “We have clarity on the non-clinical data needed to support the start of our Phase 2 study of COYA-302 in patients with ALS and we are fully aligned with the FDA. We are confident in the path forward towards the completion of this important potential pivotal trial. Following FDA acceptance of the Coya 302 IND in ALS, we expect to submit the IND for COYA 302 in FTD, likely in the second half of 2025.”
Coya CEO Arun Swaminathan, Ph.D. said:
“As the new CEO of Coya, I am very encouraged by our progress in 2024. I believe our progress opens a wide array of strategic opportunities in 2025, both with existing and new partners. I will be keenly focused on delivering shareholder value over the next year.
“During the third quarter of 2024 we continued to advance our pipeline of neurodegenerative treatments, all aimed at neurodegenerative diseases with high unmet need, including AD, PD, and ALS.
“Our drug candidates all target neuroinflammation, which we see as a major contributing factor towards disease progression in the neurological conditions we are addressing. Moreover, our approach to potential combination therapies for treatment of these neurodegenerative diseases differentiates us from other companies and offers, what we believe, a new treatment paradigm that could lead to the creation of meaningful shareholder value.
“We anticipate 2025 will be a busy and productive year filled with multiple milestones, clinical data and catalysts. In Q1 of 2025, we will be presenting additional clinical data from the investigator-initiated phase 2 trial in AD and later in the year clinical data from another investigator-initiated clinical trial in FTD, this time with the combination of LD IL-2 and CTLA-4 Ig. We are also excited to begin our Coya sponsored phase 2 trials for our combination biologic COYA 302 in both ALS and FTD.
“During the CTAD conference in
“We also believe there is potential for strategic opportunities combining COYA-301 with other therapeutic agents as potential therapeutics for patients with AD or other neurodegenerative and autoimmune diseases.
“Finally, our recent capital raise provides additional flexibility and cushion for us to execute on our corporate, clinical, and regulatory goals. As of October 31, 2024, our interim cash and cash equivalents (unaudited) was
Unaudited Financial Results
As of September 30, 2024, Coya had cash and cash equivalents of
Research and development expenses were
General and administrative expenses were
Net loss was
About Coya Therapeutics, Inc.
Headquartered in
Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
COYA 302 – the Company’s lead biologic investigational product or "Pipeline in a Product" – is a proprietary combination of COYA 301 (Coya’s proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration with a unique dual mechanism of action that is now being developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson’s Disease, and Alzheimer’s Disease. Its multi-targeted approach enhances the number and anti-inflammatory function of Tregs and simultaneously lowers the expression of activated microglia and the secretion of pro-inflammatory mediators. This synergistic mechanism may lead to the re-establishment of immune balance and amelioration of inflammation in a sustained and durable manner that may not be achieved by either low-dose IL-2 or CTLA4-Ig alone.
For more information about Coya, please visit www.coyatherapeutics.com.
Forward-Looking Statements
This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.
Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or will occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
CONDENSED BALANCE SHEETS |
||||||||
|
|
September 30, |
|
December 31, |
||||
|
|
2024 |
|
2023 |
||||
|
|
(unaudited) |
|
|
||||
Assets |
|
|
|
|
||||
Current assets: |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
31,057,395 |
|
|
$ |
32,626,768 |
|
Collaboration receivable |
|
|
- |
|
|
|
7,500,000 |
|
Prepaids and other current assets |
|
|
4,449,006 |
|
|
|
1,069,557 |
|
Total current assets |
|
|
35,506,401 |
|
|
|
41,196,325 |
|
Fixed assets, net |
|
|
45,429 |
|
|
|
65,949 |
|
Total assets |
|
$ |
35,551,830 |
|
|
$ |
41,262,274 |
|
|
|
|
|
|
||||
Liabilities and Stockholders' Equity |
|
|
|
|
||||
Current liabilities: |
|
|
|
|
||||
Accounts payable |
|
$ |
336,722 |
|
|
$ |
1,155,656 |
|
Accrued expenses |
|
|
1,409,235 |
|
|
|
2,973,215 |
|
Deferred collaboration revenue |
|
|
573,089 |
|
|
|
923,109 |
|
Total current liabilities |
|
|
2,319,046 |
|
|
|
5,051,980 |
|
Deferred collaboration revenue |
|
|
1,222,596 |
|
|
|
574,685 |
|
Total liabilities |
|
|
3,541,642 |
|
|
|
5,626,665 |
|
|
|
|
|
|
||||
Stockholders' equity: |
|
|
|
|
||||
Series A convertible preferred stock, |
|
|
- |
|
|
|
- |
|
Common stock, |
|
|
1,523 |
|
|
|
1,441 |
|
Additional paid-in capital |
|
|
69,830,059 |
|
|
|
61,501,801 |
|
Subscription receivable |
|
|
- |
|
|
|
(11,250 |
) |
Accumulated deficit |
|
|
(37,821,394 |
) |
|
|
(25,856,383 |
) |
Total stockholders' equity |
|
|
32,010,188 |
|
|
|
35,635,609 |
|
Total liabilities and stockholders' equity |
|
$ |
35,551,830 |
|
|
$ |
41,262,274 |
|
CONDENSED UNAUDITED INTERIM STATEMENTS OF OPERATIONS |
||||||||||||||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
Collaboration revenue |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
3,552,109 |
|
|
$ |
— |
|
Operating expenses: |
|
|
|
|
|
|
|
|
||||||||
Research and development |
|
|
2,223,903 |
|
|
|
1,592,232 |
|
|
|
9,928,214 |
|
|
|
3,891,896 |
|
In-process research and development |
|
|
— |
|
|
|
— |
|
|
|
25,000 |
|
|
|
350,000 |
|
General and administrative |
|
|
2,219,545 |
|
|
|
1,964,990 |
|
|
|
6,747,790 |
|
|
|
5,456,087 |
|
Depreciation |
|
|
6,841 |
|
|
|
6,841 |
|
|
|
20,521 |
|
|
|
20,521 |
|
Total operating expenses |
|
|
4,450,289 |
|
|
|
3,564,063 |
|
|
|
16,721,525 |
|
|
|
9,718,504 |
|
Loss from operations |
|
|
(4,450,289 |
) |
|
|
(3,564,063 |
) |
|
|
(13,169,416 |
) |
|
|
(9,718,504 |
) |
Other income: |
|
|
|
|
|
|
|
|
||||||||
Other income |
|
|
428,871 |
|
|
|
142,089 |
|
|
|
1,204,405 |
|
|
|
464,693 |
|
Net loss |
|
$ |
(4,021,418 |
) |
|
$ |
(3,421,974 |
) |
|
$ |
(11,965,011 |
) |
|
$ |
(9,253,811 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Per share information: |
|
|
|
|
|
|
|
|
||||||||
Net loss per share of common stock, basic and diluted |
|
$ |
(0.26 |
) |
|
$ |
(0.34 |
) |
|
$ |
(0.80 |
) |
|
$ |
(0.94 |
) |
Weighted-average shares of common stock outstanding, basic and diluted |
|
|
15,221,308 |
|
|
|
9,947,915 |
|
|
|
14,866,089 |
|
|
|
9,873,387 |
|
CONDENSED UNAUDITED INTERIM STATEMENTS OF CASH FLOWS |
||||||||
|
|
Nine Months Ended
|
||||||
|
|
2024 |
|
2023 |
||||
Cash flows from operating activities: |
|
|
|
|
||||
Net loss |
|
$ |
(11,965,011 |
) |
|
$ |
(9,253,811 |
) |
Adjustment to reconcile net loss to net cash used in operating activities: |
|
|
|
|
||||
Depreciation |
|
|
20,521 |
|
|
|
20,521 |
|
Stock-based compensation, including the issuance of restricted stock |
|
|
1,872,990 |
|
|
|
634,249 |
|
Acquired in-process research and development assets |
|
|
25,000 |
|
|
|
350,000 |
|
Changes in operating assets and liabilities: |
|
|
|
|
||||
Collaboration receivable |
|
|
7,500,000 |
|
|
|
- |
|
Prepaids and other current assets |
|
|
(3,379,449 |
) |
|
|
314,910 |
|
Accounts payable |
|
|
(773,956 |
) |
|
|
(177,911 |
) |
Accrued expenses |
|
|
(1,477,041 |
) |
|
|
(835,689 |
) |
Deferred collaboration revenue |
|
|
297,891 |
|
|
|
- |
|
Net cash used in operating activities |
|
|
(7,879,055 |
) |
|
|
(8,947,731 |
) |
Cash flows from investing activities: |
|
|
|
|
||||
Purchase of in-process research and development assets |
|
|
(25,000 |
) |
|
|
(350,000 |
) |
Net cash used in investing activities |
|
|
(25,000 |
) |
|
|
(350,000 |
) |
Cash flows from financing activities: |
|
|
|
|
||||
Proceeds from sale of common stock upon initial public offering, net of offering costs |
|
|
- |
|
|
|
14,250,311 |
|
Proceeds from sale of common stock, net of offering costs |
|
|
4,943,668 |
|
|
|
- |
|
Proceeds from subscription receivable |
|
|
11,250 |
|
|
|
- |
|
Payment of financing costs related to the 2023 Private Placement |
|
|
(131,918 |
) |
|
|
- |
|
Proceeds from the exercise of stock options |
|
|
1,975 |
|
|
|
- |
|
Proceeds from the exercise of warrants |
|
|
1,509,707 |
|
|
|
- |
|
Net cash provided by financing activities |
|
|
6,334,682 |
|
|
|
14,250,311 |
|
Net increase in cash and cash equivalents |
|
|
(1,569,373 |
) |
|
|
4,952,580 |
|
Cash and cash equivalents as of beginning of the period |
|
|
32,626,768 |
|
|
|
5,933,702 |
|
Cash and cash equivalents as of end of the period |
|
$ |
31,057,395 |
|
|
$ |
10,886,282 |
|
|
|
|
|
|
||||
Supplemental disclosures of non-cash financing activities: |
|
|
|
|
||||
Conversion of convertible preferred stock upon initial public offering |
|
$ |
- |
|
|
$ |
8,793,637 |
|
Conversion of convertible promissory notes upon initial public offering |
|
$ |
- |
|
|
$ |
12,965,480 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106135734/en/
Investor Contact
David
david@coyatherapeutics.com
CORE IR
Bret Shapiro
brets@coreir.com
561-479-8566
Media Contact
Kati Waldenburg
media@coyatherapeutics.com
212-655-0924
Source: Coya Therapeutics, Inc.
FAQ
What were Coya Therapeutics (COYA) Q3 2024 financial results?
What major clinical developments did COYA announce in Q3 2024?